Supplementary Table S4 from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Year: 2024
Type: supplementary-materials
Abstract: Outcomes by Subgroups of Primary Site, Adjuvant Radiation, and R0/R1 Resection Margin Status
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402803291
